DaVita Inc. specializes in delivering essential kidney dialysis treatments and comprehensive renal care to individuals grappling with chronic kidney failure. The company ...
Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer
DVA's IKC momentum, higher 2026 guidance and technology investments support growth, while reimbursement and payer-mix risks cloud the outlook.
In the latest trading session, DaVita HealthCare (DVA) closed at $239.46, marking a +1.33% move from the previous day.
DENVER, July 21, 2026 /PRNewswire/ -- DaVita Inc. (NYSE: DVA), announced today that it will hold its quarterly conference call to discuss second quarter results on Tuesday, August 4, 2026, at 5:00 p.m. Eastern Time.
DaVita HealthCare (DVA) reached $236.97 at the closing of the latest trading day, reflecting a +1.26% change compared to its last close.
In the closing of the recent trading day, DaVita HealthCare (DVA) stood at $234.01, denoting a +1.04% move from the preceding trading day.
DVA's IKC momentum, higher 2026 guidance and technology investments support growth, while reimbursement and payer-mix risks cloud the outlook.
In the latest trading session, DaVita HealthCare (DVA) closed at $239.46, marking a +1.33% move from the previous day.
DENVER, July 21, 2026 /PRNewswire/ -- DaVita Inc. (NYSE: DVA), announced today that it will hold its quarterly conference call to discuss second quarter results on Tuesday, August 4, 2026, at 5:00 p.m. Eastern Time.
DaVita HealthCare (DVA) reached $236.97 at the closing of the latest trading day, reflecting a +1.26% change compared to its last close.
In the closing of the recent trading day, DaVita HealthCare (DVA) stood at $234.01, denoting a +1.04% move from the preceding trading day.
DaVita Inc. has more than doubled in share price within six months, driven by a strong Q1 '26 beat and a favorable court ruling. DVA fundamentals and long-term prospects remain largely unchanged, with 2026E AEPS recovery now expected at 30%+ and 10–16% annualized growth through 2028. I sold over 95% of my DVA position as the valuation exceeded $210/share, far above my fair value target of $130/share.
In the closing of the recent trading day, DaVita HealthCare (DVA) stood at $232.8, denoting a +1.45% move from the preceding trading day.
Greg Abel may have taken over as CEO, but he's not the only one making key investment decisions at Berkshire Hathaway. Berkshire's positions in DaVita and SiriusXM, reportedly selected by Ted Weschler, who manages a portion of the portfolio, have outperformed so far in 2026.
DaVita HealthCare (DVA) reached $230.72 at the closing of the latest trading day, reflecting a -1.53% change compared to its last close.
ADM, CASY, DVA, CVS and BEN top a list of five non-AI S&P 500 stocks that surged more than 30% in 1H 2026 and still show momentum for 2H.
On July 02, 2026, DaVita Inc (DVA) shares rose 3.0% to a current price of $234.91. The stock has experienced significant price appreciation recently, with a 10.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
DVA, FIVE, and PBI it to the Zacks Rank #1 (Strong Buy) growth stocks list on July 2, 2026.
DVA is advancing kidney care through IKC expansion, CMS CKCC progress and AI-driven dialysis scheduling improvements.
DVA, FIVE, and PBI it to the Zacks Rank #1 (Strong Buy) growth stocks list on June 30, 2026.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
In the most recent trading session, DaVita HealthCare (DVA) closed at $217.04, indicating a +1.72% shift from the previous trading day.
Analysts don't like to put "sell" ratings on S&P 500 stocks. So the fact they're willing to do it with some is worth your attention.
LYB, HRB and DVA made it to the Zacks Rank #1 (Strong Buy) growth stocks list on June 26th, 2026.
The latest trading day saw DaVita HealthCare (DVA) settling at $213.04, representing a +1% change from its previous close.
DVA is expanding kidney care through outpatient, home-centered and value-based programs while investing in AI-enabled scheduling.
HRB, DVA and PBI made it to the Zacks Rank #1 (Strong Buy) growth stocks list on June 24th, 2026.
DaVita and Fresenius Medical Care are taking different paths in kidney care, but which stock offers stronger upside now? Let's dive in.
Medical stocks like Centene, DaVita and BrightSpring could rally as SpaceX IPO-fueled market optimism lifts broader sector sentiment.
HRB, DVA and PBI made it to the Zacks Rank #1 (Strong Buy) growth stocks list on June 22nd, 2026.
DaVita HealthCare (DVA) closed the most recent trading day at $207.91, moving 1.27% from the previous trading session.
Investors target stocks that have been on a bullish run. Stocks like MUSA, DVA, HPE and VSH are seeing price strength, and the momentum is likely to continue.
DVA is expanding kidney care beyond hospitals with IKC, digital tools and AI to improve coordination, lower costs and support patients.
ECPG, DK and DVA made it to the Zacks Rank #1 (Strong Buy) value stocks list on June 17, 2026.
DVA, FIVE, and PBI it to the Zacks Rank #1 (Strong Buy) growth stocks list on June 17, 2026.
DaVita operates more than 3,200 dialysis centers globally, serving roughly 295,000 patients with a dominant market share in kidney care. Encompass Health is a leader in inpatient rehabilitation with double-digit revenue growth and higher net margins than its peer in this matchup.
DVA, FIVE, and PBI it to the Zacks Rank #1 (Strong Buy) growth stocks list on June 15, 2026.
Banking giant BMO, Astronics, DaVita and Intercorp Financial make new highs Friday as the stock market aims to rebound.
In the most recent trading session, DaVita HealthCare (DVA) closed at $203.83, indicating a +2.66% shift from the previous trading day.
DaVita HealthCare (DVA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
PRTH, DVA and BFH made it to the Zacks Rank #1 (Strong Buy) value stocks list on June 11, 2026.
DVA, HRB, and PBI it to the Zacks Rank #1 (Strong Buy) growth stocks list on June 11, 2026.
DVA expands its IKC platform, tops CKCC savings in first-quarter 2026 and rolls out AI ScheduleHub to boost scheduling and staffing.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
An aging population and rising telehealth and AI adoption boost demand in the Zacks Medical - Outpatient and Home Healthcare industry. DGX, DVA, LFST and AVAH stand to benefit.
DVA, XPO, and PBI it to the Zacks Rank #1 (Strong Buy) growth stocks list on June 9, 2026.
THG, DVA and PLOW made it to the Zacks Rank #1 (Strong Buy) value stocks list on June 9, 2026.
DVA expands kidney-care reach with integrated CKD/ESKD coordination and 2026 AI scheduling tech to boost dialysis efficiency.
DaVita HealthCare (DVA) reported earnings 30 days ago. What's next for the stock?
HRB, DVA and VLO made it to the Zacks Rank #1 (Strong Buy) growth stocks list on June 4th, 2026.
DVA raises guidance on stronger dialysis volumes and reimbursement gains, but rising patient-care and technology costs could squeeze margins.
HRB, DVA and LCUT made it to the Zacks Rank #1 (Strong Buy) growth stocks list on June 2nd, 2026.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
CNC, SANM and DVA made it to the Zacks Rank #1 (Strong Buy) growth stocks list on May 26, 2026.
LCUT, GECC, ARKO, PBI and DVA have been added to the Zacks Rank #1 (Strong Buy) List on May 26, 2026.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
These four GARP stocks combine discounted PEG ratios with strong growth potential, offering investors a balanced strategy for 2026.
Investors target stocks that have been on a bullish run. Stocks like MUSA, DVA, MCHP and CVE are seeing price strength, and the momentum is likely to continue.
GPRE, DVA and SNX made it to the Zacks Rank #1 (Strong Buy) value stocks list on May 21, 2026.
DVA, TAL, and LCUT it to the Zacks Rank #1 (Strong Buy) growth stocks list on May 21, 2026.
UVE, LCUT and DVA made it to the Zacks Rank #1 (Strong Buy) value stocks list on May 19, 2026.
DVA, PBI, and LCUT it to the Zacks Rank #1 (Strong Buy) growth stocks list on May 19, 2026.
DaVita Sets Bold 2030 Community Care Commitments After Exceeding Prior Five-Year ESG Goals PR Newswire DENVER, M
Kidney care leader launches its next chapter of measurable impact for patients, teammates, and communities. DENVER, May 18, 2026 /PRNewswire/ -- DaVita today announced its 2030 Community Care commitments, a new set of long-term goals, focused on improving patient outcomes, supporting the expansion of economic opportunity for teammates, and strengthening community and environmental resilience.
Low-PEG stocks like DaVita, AR, PBF and Popular stand out as value plays with strong growth potential and discounted valuations.
NXST, LCUT and DVA made it to the Zacks Rank #1 (Strong Buy) growth stocks list on May 14th, 2026.
DaVita Inc. (DVA) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
AR, DVA and WOOF made it to the Zacks Rank #1 (Strong Buy) growth stocks list on May 12th, 2026.
These highly ranked medical stocks have been capitalizing on their sales expansion, and their defensive or secular growth profiles could become even more attractive if an economic downturn emerges.
Does DaVita HealthCare (DVA) have what it takes to be a top stock pick for momentum investors? Let's find out.
DaVita HealthCare (DVA) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Here are three stocks with buy ranks and strong growth characteristics for investors to consider today May 8th:
ATLC, DVA and AMN made it to the Zacks Rank #1 (Strong Buy) value stocks list on May 8, 2026.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
DaVita Inc. is upgraded to a Buy following robust Q1 results and a 23% post-earnings stock surge. DVA's Q1 non-GAAP EPS of $2.87 beat consensus, with revenue up 6% year-over-year and management raising guidance. Mid-teens EPS growth is expected through 2026, with a 10%+ FCF yield and a modest P/E ratio supporting valuation.
DENVER, May 6, 2026 /PRNewswire/ -- DaVita Inc. (NYSE: DVA) today announced that its chief financial officer, Joel Ackerman, and its group vice president of investor relations, Nic Eliason, will participate in a fireside chat with investors at the BofA Securities 2026 Health Care Conference on Tuesday, May 12th, 2026 at 5:20 pm Eastern Daylight Time. To view the live webcast, visit the BofA page and create a free registration.
DVA's first-quarter 2026 results benefit from expanding margins and steady dialysis demand across its broad clinic network.
DaVita Inc. (DVA) Q1 2026 Earnings Call Transcript
DaVita HealthCare (DVA) came out with quarterly earnings of $2.87 per share, beating the Zacks Consensus Estimate of $2.41 per share. This compares to earnings of $2 per share a year ago.
DaVita on Tuesday raised its forecast for annual adjusted profit after beating Wall Street estimates for first-quarter results, betting on steady demand for its kidney dialysis services.
DENVER, May 5, 2026 /PRNewswire/ -- DaVita Inc. (NYSE: DVA) announced financial and operating results for the quarter ended March 31, 2026. "DaVita's foundation is clinical excellence, driven by operating rigor that produces durable results," said Javier Rodriguez, CEO of DaVita Inc. "We have consistently delivered exceptional clinical outcomes and strong financial performance, and this quarter is no exception.
